Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Trulicity ® (dulaglutid) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The Researching CV Events with a Weekly INcretin in Diabetes (REWIND) study was an event-driven, randomized, double-blind, phase 3 study evaluating once-weekly dulaglutide 1.5 mg treatment compared with placebo when added to standard of care on a composite endpoint of MACE-3 in adults with T2DM and established CV disease and/or risk factors.1,2
Since the REWIND study did not include active comparators, there is no data available on how dulaglutide would compare with other GLP-1 receptor agonists in regards to cardiovascular outcomes.1
Design
The study evaluated the risk of MACE with once-weekly dulaglutide 1.5 mg treatment compared with placebo when added to standard of care in patients 50 years of age and older with T2DM and CV risk factors.3
The primary CV outcome measure was the first occurrence of the composite MACE-3, which includes death due to CV causes, nonfatal MI, or nonfatal stroke.3
Results
Dulaglutide 1.5 mg significantly reduced MACE-3 when compared to placebo (HR=0.88 [95% CI 0.79, 0.99]; p=.026), demonstrating a decrease in CV events and showing safety in a population that included a majority of participants without established CV disease.2
Other GLP-1 Receptor Agonists CV Outcome Trials
Per regulatory guidance, CV outcome trials were conducted for other marketed GLP-1 receptor agonists. The table below describes the CV outcomes across the GLP-1 receptor agonist class(Table 1).
Table 1. Key Characteristics of GLP-1 Receptor Agonist CV Outcome Trials
|
ELIXA4 |
LEADER5 |
SUSTAIN-66 |
EXSCEL7 |
Harmony8 |
|
GLP-1 RA |
lixisenatide daily |
liraglutide daily |
semaglutide weekly |
exenatide weekly |
albiglutide weekly |
dulaglutide |
Dose |
20 mcg |
1.8 mg |
0.5 mg or 1 mg |
2.0 mg |
30-50 mg |
1.5 mg |
# of Patients |
6068 |
9340 |
3297 |
14752 |
9463 |
9901 |
Mean age, y |
60 |
64 |
65 |
62 (median) |
64 |
66 |
Female, % |
31 |
36 |
39 |
38 |
31 |
46 |
Prior CVD,a % |
100b |
81c |
83d |
73e |
100f |
31g |
BMI, kg/m2 |
30 |
33 |
33 |
32h |
32 |
32 |
HbA1c, % |
7.7 |
8.7 |
8.7 |
8.0h |
8.7 |
7.3 |
# of CV eventsi |
805 |
1302 |
254 |
1744 |
766 |
1257 |
Median follow-up, y |
2.1 |
3.8 |
2.1 |
3.2 |
1.6 |
5.4 |
Primary Outcome |
MACE-4 |
MACE-3 |
MACE-3 |
MACE-3 |
MACE-3 |
MACE-3 |
Abbreviations: BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; CKD = chronic kidney disease; CRF = chronic renal failure; CV = cardiovascular; CVD = cardiovascular disease; ELIXA = the Evaluation of Lixisenatide in Acute Coronary Syndrome trial; EXSCEL = the EXenatide Study of Cardiovascular Event Lowering; GLP-1 RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated hemoglobin; HF = heart failure; LEADER = the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; MACE = major adverse cardiovascular events; MACE-3 = 3-component MACE; MACE-4 = 4-component MACE; MI = myocardial infarction; p = p-value; PAD = peripheral artery disease; PVD = peripheral vascular disease; REWIND = Researching Cardiovascular Events with a Weekly INcretin in Diabetes; SUSTAIN 6 = the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes.
a Definitions of prior CVD vary by study, thus making cross-trial comparisons difficult.
b ELIXA: acute coronary event within 180 days before screening.
c LEADER: CVD, cerebrovascular disease, PVD, CRF, CHF.
d 83.0% established CVD including CKD of stage 3 or higher.
e EXSCEL: 73% at least one prior CV event (70% CAD, 24% PAD, 22% cerebrovascular disease).
f HARMONY: established CVD includes at least one of the following: CAD, cerebrovascular disease, or PAD.
g REWIND: ≥1 of the following, prior MI, ischemic stroke, unstable angina, revascularization, hospitalization for ischaemia-related events, or documented myocardial ischemia.
h Median.
GLP-1 Receptor Agonist CV Outcome Trials Compared to US T2DM Population
Boye et al examined the generalizability of results from CV outcome trials in the US T2DM population with results from the 4 GLP-1 receptor agonist CV outcome trials
EXSCEL
LEADER
REWIND, and
SUSTAIN-6.9
When inclusion and exclusion criteria for each trial were applied to the US T2DM population, eligibility were
42.6% for REWIND
15.9% for EXSCEL
13.0% for SUSTAIN-6, and
12.9% for LEADER.9
1. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49. https://doi.org/10.1111/dom.13028
2. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
3. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49. https://doi.org/10.1111/dom.13028
4. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-2257. https://doi.org/10.1056/NEJMoa1509225.
5. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. https://doi.org/10.1056/NEJMoa1603827.
6. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
7. Holman RR, Bethel MA, Mentz RJ, et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-1239. https://doi.org/10.1056/NEJMoa1612917
8. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. The Lancet. 2018;392(10157):1519-1529. https://doi.org/10.1016/S0140-6736(18)32261-X
9. Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States [published online February 3, 2019]. Diabetes Obes Metab. https://doi.org/10.1111/dom.13649
Glossary
CV = cardiovascular
LEADER = Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results
EXSCEL = EXenatide Study of Cardiovascular Event Lowering
GLP-1 = glucagon-like peptide-1
HR = hazard ratio
MACE = major adverse cardiovascular event
MACE-3 = major adverse cardiovascular events (death due to cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)
MI = myocardial infarction
REWIND = Researching cardiovascular Events with a Weekly INcretin in Diabetes
SUSTAIN-6 = trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes
T2DM = type 2 diabetes mellitus
Datum fӧr senaste ӧversyn 2019 M08 05